STOCKHOLM, April 27, 2022 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today
announces that the Annual Report for 2021 now is available at the
company's website: www.calliditas.com.
This information is information that Calliditas Therapeutics
AB is obliged to make public pursuant to the Securities Markets
Act. The information was submitted for publication at 18:00 CET on April 27,
For further information, please contact:
Marie Galay, IR Manager,
Tel.: +44 79 55 12 98 45, email: firstname.lastname@example.org
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, TARPEYOTM (budesonide) delayed release capsules, has been
approved by the FDA and is the subject of a marketing authorization
application (MAA) with the European Medicines Agency (EMA).
Additionally, Calliditas is conducting a pivotal clinical trial
with its NOX inhibitor product candidate setanaxib in primary
biliary cholangitis and is initiating a head and neck cancer Phase
2 trial with setanaxib. Calliditas' common shares are listed on
Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares
are listed on the Nasdaq Global Select Market (ticker: CALT).
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Calliditas' strategy, commercialization efforts, business
plans, regulatory submissions, clinical development plans and
focus. The words "may," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "project," "potential," "continue," "target," and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties, and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, any related to Calliditas' business, operations,
continued EMA review and approval for NEFECON, market acceptance of
NEFECON/TARPEYO, safety or efficacy of NEFECON/TARPEYO, clinical
trials, supply chain, strategy, goals and anticipated timelines,
competition from other biopharmaceutical companies, and other risks
identified in the section entitled "Risk Factors" in Calliditas'
reports filed with the Securities and Exchange Commission.
Calliditas cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. Calliditas disclaims any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions, or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent Calliditas' views only as
of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
This information was brought to you by Cision
The following files are available for download:
Annual report 2021
SOURCE Calliditas Therapeutics